Literature DB >> 1543816

beta-Galactosidase from Aspergillus niger in adult lactose malabsorption: a double-blind crossover study.

G R Corazza1, G Benati, M Sorge, A Strocchi, G Calza, G Gasbarrini.   

Abstract

An assessment was made of the efficacy of a beta-galactosidase, obtained from Aspergillus niger and added to intact milk, in decreasing lactose malabsorption and intolerance. Sixteen adult patients with malabsorption and intolerance to this sugar were studied in a double-blind crossover study vs. placebo. A 5-hour hydrogen breath test was used to assess malabsorption of lactose contained in 400 ml milk. When compared with placebo, the addition of exogenous lactase to intact milk caused a statistically significant reduction in the maximum breath H2 concentration (P less than 0.01) and in the cumulative H2 excretion (P less than 0.005). In the same way, the cumulative index for gastrointestinal intolerance was significantly lower (P less than 0.005) after the ingestion of lactase-added milk. This study demonstrates that enzyme replacement therapy, with beta-galactosidases obtained from Aspergillus niger, is effective in decreasing lactose malabsorption and its consequent intolerance in adult subjects with lactase deficiency.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1543816     DOI: 10.1111/j.1365-2036.1992.tb00545.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  2 in total

Review 1.  Management and treatment of lactose malabsorption.

Authors:  Massimo Montalto; Valentina Curigliano; Luca Santoro; Monica Vastola; Giovanni Cammarota; Raffaele Manna; Antonio Gasbarrini; Giovanni Gasbarrini
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

2.  Effects of exogenous lactase administration on hydrogen breath excretion and intestinal symptoms in patients presenting lactose malabsorption and intolerance.

Authors:  Ivan Ibba; Agnese Gilli; Maria Francesca Boi; Paolo Usai
Journal:  Biomed Res Int       Date:  2014-05-25       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.